Anke Bio Announces Clinical Trial Approval for PA3-17 Injection's New Indication in Pediatric and Adolescent Patients

Source: Securities Times

People's Finance News, March 4thANKEBIO(300009) Announcement on March 4, ANKEBIO's participating companies, Bo sheng ji medicine science and technology (suzhou) co., LTD, and Bo sheng ji Anke Cell Technology Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for a new indication of their self-developed PA3-17 injection has been approved by the National Medical Products Administration, allowing the product to proceed with clinical trials for the treatment of relapsed/refractory T lymphoblastic leukemia/lymphoma in children and adolescents.